shares of Acorda Therapeutics Inc (ACOR) on
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. The company is headquartered in Ardsley, New York and currently employs 474 full-time employees. The firm focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The firm also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The firm has a pipeline of neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and MS. The firm’s product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.